Liquid Biopsy Market Headed for Growth and Global Expansion by 2026

Liquid Biopsy Market Headed for Growth and
Global Expansion by 2026
Global Liquid Biopsy Market by Products & Services (Reagents & Kits,
Equipment, and Services), By Sample (Cell Free DNA, Circulating Tumor Cells,
and Exosomes), By Application (Oncology Testing, Non-Invasive Prenatal
Testing, and Transplant Care), By End User (Hospitals, Research Laboratories,
Diagnostic Laboratories, and Patients) and by Geography - Trends and Forecast
to 2025
Liquid biopsy gained popularity among physicians owing to increasing importance of precision
medicine and advantages offered by the liquid biopsy over conventional biopsy techniques. Clinical
diagnosis of tumors is done by pathological testing and medical imaging in which pathological testing
involves tissue biopsies, molecular pathology tests, and serological indicators tests. Among these
techniques tissue biopsy is considered as a gold standard for diagnosis. However, it has certain
disadvantages such as difficulty in obtaining tissues from terminal cancer patients, complications due to
sampling, and result difference due to tumor heterogeneity. Liquid biopsy provides more accurate
results and offers more advantages over conventional techniques. It uses circulating tumor cell
detection and cell free DNA etc. techniques for early detection of the cancer. Click To Read More On
Liquid Biopsy Market.
Market Dynamics
Factors such as rising prevalence of various cancers, rising demand for minimally invasive procedures,
and advantages offered by liquid biopsy over conventional tissue biopsy are supporting growth of the
liquid biopsy market. Liquid biopsy offers advantages over conventional tissue biopsy such as early
disease detection, real-time monitoring of the metastasis and actual treatment response, detection of
primary tumors and metastasis through simple and non-invasive tests, and may be cheaper than
conventional biopsy. Furthermore, prevalence of various cancers is increasing and according to
National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the
U.S., with an around 595,690 deaths from the disease. The number of people with cancer is expected to
rise to 19 million by 2024, indicating need for early disease diagnosis and treatment. Demand for
minimally invasive treatments is also increasing as tissue biopsy is an invasive approach for cancer
diagnosis, wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid
biopsy market.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1223
A liquid biopsy is a simple and non-invasive technique that enables to discover a range of information
about a tumor through a simple blood sample. Some of the commercially available liquid biopsy tests
for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid
biopsy assays. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations,
evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is
quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma that is
analyzed for tumor DNA. Potential of liquid biopsies to detect disease progression or treatment
resistance long before it would trigger clinical symptoms or appear on imaging scans is major factor
driving growth of liquid biopsy market.
Tissue samples removed for biopsy many not show all mutations as cancer has multiple genetic
mutations, whereas liquid biopsies offer an improved chance of detecting these genetic changes.
Moreover, the efficiency of liquid biopsy to improve progression and survival rates in cancer is major
factor driving growth of the market.
Manufacturers are focusing on development of new tests in the liquid biopsy market and this is
expected to bolster growth of the liquid biopsy market over the forecast period
Established as well as small players in the liquid biopsy market are actively focusing on research and
development of methods in liquid biopsy through collaborations. For instance, Biodesix—a U.S.-based
company—developed a novel way of extract circulating RNA from plasma in November 2017, in
collaboration with Norgen Biotek. Moreover, Precipio—a U.S.-based organization, entered into merger
agreement with Transgenomic, in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies,
which preferentially enriches mutant DNA sequences over wild-type DNA through selective
amplification. HaploX Biotechnology—a China-based company—raised US$ 32 Mn in financing, in
January 2018, in order to integrate liquid biopsy technology, artificial intelligence, and gene
sequencing.
Competitive Landscape
Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera,
Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific
Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc.,
CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Liquid biopsy gained popularity among physicians owing to increasing importance of precision medicine and advantages offered by the liquid biopsy over conventional biopsy techniques.

Download Report